Chemotherapy + Pembrolizumab + Ramucirumab
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Lung Non-Small Cell Carcinoma
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Trial Timeline
Mar 14, 2023 → Mar 15, 2028
NCT ID
NCT05633602About Chemotherapy + Pembrolizumab + Ramucirumab
Chemotherapy + Pembrolizumab + Ramucirumab is a phase 3 stage product being developed by Eli Lilly for Recurrent Lung Non-Small Cell Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT05633602. Target conditions include Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Lung Non-Small Cell Carcinoma were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05633602 | Phase 3 | Active |
Competing Products
20 competing products in Recurrent Lung Non-Small Cell Carcinoma